SureSelect Cancer Pan Heme Assay

RUO

SureSelect Cancer Pan Heme Assay is a hybrid capture-based NGS assay that interrogates both DNA and RNA to deliver comprehensive genomic profiling for hematologic malignancies. The assay was curated and independently validated by leading hematology experts at Roswell Park Comprehensive Cancer Center.

The complete assay includes SureSelect probes and reagents or Magnis SureSelect kits, paired with optimized software for accurate variant calling and reporting. This end-to-end solution delivers rapid turnaround times through a scalable, automated workflow that’s cost-effective and easy to implement.

For Research Use Only. Not for use in diagnostic procedures.

Cancer

Features

Expertly Curated Content. Panel content thoughtfully curated by world-renowned experts in hematological diseases at Roswell Park Comprehensive Cancer Center (Buffalo, New York).
Comprehensive Profiling. Integrated DNA/RNA analysis that detects all classes of genomic alterations – SNVs, indels, CNVs, FLT3-ITDs, KMT2A PTDs, IGH/K/L rearrangements, and gene fusions.
Trusted Assay. Implemented by a CAP/CLIA-certified lab at Roswell Park, after rigorous validation as mandated by the New York State Department of Health.
Rapid, Turnkey Solution. 48-hour turnaround time from sample to report, leveraging fully automated NGS library preparation and target enrichment, as well as variant analysis and reporting.
Easy Implementation. Simple and cost-effective in-house implementation powered by Magnis automation and optimized QCI software.
Complete Control. Full control of cancer samples, budget, sequencing data, and turnaround time. Build genomic expertise while avoiding pricey send-out services.

Specifications


Automation Compatible	Yes
Hybridization Time	90-minute

Return to top

Featured

SureSelect Cancer Pan Heme Assay

Product Details

Customers Also Viewed These Products